» Articles » PMID: 22019144

Effect of Radiotherapy After Breast-conserving Surgery on 10-year Recurrence and 15-year Breast Cancer Death: Meta-analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2011 Oct 25
PMID 22019144
Citations 1372
Authors
Affiliations
Soon will be listed here.
Abstract

Background: After breast-conserving surgery, radiotherapy reduces recurrence and breast cancer death, but it may do so more for some groups of women than for others. We describe the absolute magnitude of these reductions according to various prognostic and other patient characteristics, and relate the absolute reduction in 15-year risk of breast cancer death to the absolute reduction in 10-year recurrence risk.

Methods: We undertook a meta-analysis of individual patient data for 10,801 women in 17 randomised trials of radiotherapy versus no radiotherapy after breast-conserving surgery, 8337 of whom had pathologically confirmed node-negative (pN0) or node-positive (pN+) disease.

Findings: Overall, radiotherapy reduced the 10-year risk of any (ie, locoregional or distant) first recurrence from 35·0% to 19·3% (absolute reduction 15·7%, 95% CI 13·7-17·7, 2p<0·00001) and reduced the 15-year risk of breast cancer death from 25·2% to 21·4% (absolute reduction 3·8%, 1·6-6·0, 2p=0·00005). In women with pN0 disease (n=7287), radiotherapy reduced these risks from 31·0% to 15·6% (absolute recurrence reduction 15·4%, 13·2-17·6, 2p<0·00001) and from 20·5% to 17·2% (absolute mortality reduction 3·3%, 0·8-5·8, 2p=0·005), respectively. In these women with pN0 disease, the absolute recurrence reduction varied according to age, grade, oestrogen-receptor status, tamoxifen use, and extent of surgery, and these characteristics were used to predict large (≥20%), intermediate (10-19%), or lower (<10%) absolute reductions in the 10-year recurrence risk. Absolute reductions in 15-year risk of breast cancer death in these three prediction categories were 7·8% (95% CI 3·1-12·5), 1·1% (-2·0 to 4·2), and 0·1% (-7·5 to 7·7) respectively (trend in absolute mortality reduction 2p=0·03). In the few women with pN+ disease (n=1050), radiotherapy reduced the 10-year recurrence risk from 63·7% to 42·5% (absolute reduction 21·2%, 95% CI 14·5-27·9, 2p<0·00001) and the 15-year risk of breast cancer death from 51·3% to 42·8% (absolute reduction 8·5%, 1·8-15·2, 2p=0·01). Overall, about one breast cancer death was avoided by year 15 for every four recurrences avoided by year 10, and the mortality reduction did not differ significantly from this overall relationship in any of the three prediction categories for pN0 disease or for pN+ disease.

Interpretation: After breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth. These proportional benefits vary little between different groups of women. By contrast, the absolute benefits from radiotherapy vary substantially according to the characteristics of the patient and they can be predicted at the time when treatment decisions need to be made.

Funding: Cancer Research UK, British Heart Foundation, and UK Medical Research Council.

Citing Articles

Understanding the early molecular changes associated with radiation therapy-A preliminary bulk RNA sequencing study.

Miller A, De May H, Rou D, Agarwal J, Jeyapalina S PLoS One. 2025; 20(3):e0316443.

PMID: 40029831 PMC: 11875373. DOI: 10.1371/journal.pone.0316443.


The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up.

Egelberg M, De Marchi T, Schultz N, Tran L, Karlsson P, Holmberg E BMC Cancer. 2025; 25(1):374.

PMID: 40022029 PMC: 11869729. DOI: 10.1186/s12885-025-13703-1.


Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue.

Liang X, Qin Y, Li P, Mo Y, Chen D Ther Adv Med Oncol. 2025; 17:17588359251321904.

PMID: 40012707 PMC: 11863263. DOI: 10.1177/17588359251321904.


Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis.

Taha A, Kamel H, Khlidj Y, Salem D, Saed S, Abouelmagd K Medicine (Baltimore). 2025; 104(8):e41632.

PMID: 39993075 PMC: 11857031. DOI: 10.1097/MD.0000000000041632.


A Study on Synchronous Bilateral Breast Cancer Radiotherapy Based on an Accelerator Integrated with Optical Surface Monitoring System.

Zhou Z, Dong T, Wang B, Wang Z, Zhu H, Li W Technol Cancer Res Treat. 2025; 24:15330338251322075.

PMID: 39989262 PMC: 11848896. DOI: 10.1177/15330338251322075.


References
1.
Holli K, Hietanen P, Saaristo R, Huhtala H, Hakama M, Joensuu H . Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol. 2008; 27(6):927-32. DOI: 10.1200/JCO.2008.19.7129. View

2.
Bartelink H, Horiot J, Poortmans P, Struikmans H, Van den Bogaert W, Fourquet A . Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22):3259-65. DOI: 10.1200/JCO.2007.11.4991. View

3.
Winzer K, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H . Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2009; 46(1):95-101. DOI: 10.1016/j.ejca.2009.10.007. View

4.
Potter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B . Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys. 2007; 68(2):334-40. DOI: 10.1016/j.ijrobp.2006.12.045. View

5.
Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet J . Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997; 15(3):963-8. DOI: 10.1200/JCO.1997.15.3.963. View